Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients.
Fluoxetine and placebo were compared in 89 outpatients with major depression with (n = 45) or without (n = 44) a reduced or shortened rapid eye movement latency (SREML) (< or = 65 minutes) to determine whether rapid eye movement latency (REML) predicted placebo and/or antidepressant response. Men and women were stratified based on polysomnographic recordings and then randomly assigned to receive double-blind fluoxetine (20 mg/day) or placebo for 8 weeks after a 2-week, single-blind, placebo lead-in period. Fluoxetine-treated patients demonstrated a significantly greater reduction in the Hamilton Rating Scale for Depression total score and a significantly greater response rate than placebo-treated patients in both the SREML and the combined strata. Treatment differences in the non-SREML stratum were not statistically significant. Results supported REML as a predictor of placebo nonresponse but did not predict a differential fluoxetine response in patients with SREML compared with patients without SREML.
Heiligenstein
J H
JH
Psychopharmacology Division, Lilly Research Laboratories, Indianapolis, IN 46285.
Faries
D E
DE
Rush
A J
AJ
Andersen
J S
JS
Pande
A C
AC
Roffwarg
H P
HP
Dunner
D
D
Gillin
J C
JC
James
S P
SP
Lahmeyer
H
H
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D017286:Polysomnography; D011930:Reaction Time / Q000187:drug effects*; D012895:Sleep, REM / Q000187:drug effects*; D016896:Treatment Outcome
D005473:Fluoxetine